Discussion of the clinical trial progress and importance of Apelix-Piqray

Alpelisib (Alpelisib)-Piqray has attracted great attention from the global medical community since its inception. Its targeting of breast cancer patients with PIK3CA gene mutations has made it one of the important achievements in the context of precision medicine. During the development process of this drug, clinical trials played a key role, not only verifying its efficacy and safety, but also providing a solid scientific basis for subsequent clinical applications. Piqray’s initial pivotal clinical trial focuses on hormone receptor-positive, HER2-negative, advanced breast cancer patients with PIK3CA mutations, and evaluates its efficacy in combination with fulvestrant. Although the trial did not disclose all detailed data, its overall trend shows that Piqray can significantly delay tumor progression, bringing new hope to this type of patients.

Currently,Clinical research on Piqray is still ongoing in many countries and regions, especially in the exploration of drug resistance mechanisms, expansion of new indications, and combination treatment with other drugs. These trials not only focus on breast cancer, but also try to expand its application to other PIK3CA mutation-related tumors, such as endometrial cancer, head and neck cancer, and gastric cancer, thereby exploring its broader applicability. In Asia, especially China, South Korea and Japan, multi-center studies have been carried out in recent years to evaluate its metabolic characteristics and tolerability in East Asian populations, in an attempt to resolve the possible impact of racial differences on drug efficacy.

Clinical trials also promotedPiqray’s practical optimization in drug dosage adjustment and side effect management. Since its common side effects include hyperglycemia, rash, diarrhea, etc., the trial also explored the impact of different management strategies on improving patient compliance and safety. These data play an important reference role in updating drug instructions, and also improve patients' actual treatment experience.

Reference materials:https://www.piqray.com/